IDEXX Laboratories (FRA:IX1) Cyclically Adjusted Revenue per Share: €35.84 (As of Mar. 2026)


FRA:IX1 IDEXX Laboratories Inc FRA:IX1
98 GF Score
Price €486.20
GF Value €551.89
Valuation Modestly Undervalued
View Full Analysis

What is IDEXX Laboratories Cyclically Adjusted Revenue per Share?

IDEXX Laboratories FRA:IX1 +0.14% 98 Cyclically Adjusted Revenue per Share is €35.84 as of Mar. 2026. GuruFocus rates FRA:IX1 with a GF Score™ of 98/100 and a GF Value™ of €551.89 (Modestly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

IDEXX Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was €12.310. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €35.84 for the trailing ten years ended in Mar. 2026.

During the past 12 months, IDEXX Laboratories's average Cyclically Adjusted Revenue Growth Rate was 11.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of IDEXX Laboratories was 16.30% per year. The lowest was 11.80% per year. And the median was 13.70% per year.

As of today (2026-07-11), IDEXX Laboratories's current stock price is €486.20. IDEXX Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €35.84. IDEXX Laboratories's Cyclically Adjusted PS Ratio of today is 13.57.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IDEXX Laboratories was 30.79. The lowest was 7.84. And the median was 14.78.


IDEXX Laboratories  (FRA:IX1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

IDEXX Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=486.20/35.84
=13.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IDEXX Laboratories was 30.79. The lowest was 7.84. And the median was 14.78.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


IDEXX Laboratories Cyclically Adjusted Revenue per Share Related Terms


IDEXX Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories Cyclically Adjusted Revenue per Share Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.38 26.65 29.02 34.18 34.17

IDEXX Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.59 32.21 32.73 34.17 35.84

FRA:IX1 vs A, NTRA, WAT: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, IDEXX Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEXX Laboratories Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's Cyclically Adjusted PS Ratio falls into.


FRA:IX1
98GF Score
IDEXX Laboratories Inc FRA:IX1
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEXX Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IDEXX Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=12.31/330.2130*330.2130
=12.310

Current CPI (Mar. 2026) = 330.2130.

IDEXX Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 4.572 241.018 6.264
201609 4.383 241.428 5.995
201612 4.632 241.432 6.335
201703 4.800 243.801 6.501
201706 5.040 244.955 6.794
201709 4.625 246.819 6.188
201712 4.802 246.524 6.432
201803 4.902 249.554 6.486
201806 5.611 251.989 7.353
201809 5.285 252.439 6.913
201812 5.499 251.233 7.228
201903 5.823 254.202 7.564
201906 6.264 256.143 8.075
201909 6.269 256.759 8.062
201912 6.244 256.974 8.024
202003 6.538 258.115 8.364
202006 6.553 257.797 8.394
202009 7.069 260.280 8.968
202012 6.813 260.474 8.637
202103 7.516 264.877 9.370
202106 7.913 271.696 9.617
202109 7.963 274.310 9.586
202112 8.229 278.802 9.746
202203 8.877 287.504 10.196
202206 9.593 296.311 10.691
202209 10.106 296.808 11.243
202212 9.331 296.797 10.382
202303 10.014 301.836 10.955
202306 10.371 305.109 11.224
202309 10.213 307.789 10.957
202312 9.849 306.746 10.602
202403 10.565 312.332 11.170
202406 11.180 314.175 11.751
202409 10.583 315.301 11.084
202412 11.040 315.605 11.551
202503 11.273 319.799 11.640
202506 11.876 322.561 12.158
202509 11.672 324.800 11.867
202512 11.573 324.054 11.793
202603 12.310 330.213 12.310

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €35.84 mean?
IDEXX Laboratories (FRA:IX1) has a Cyclically Adjusted Revenue per Share of €35.84 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on IDEXX Laboratories and its competitors.
Is IDEXX Laboratories' Cyclically Adjusted Revenue per Share too high?
IDEXX Laboratories' current Cyclically Adjusted Revenue per Share is €35.84. Overall, IDEXX Laboratories has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Cyclically Adjusted Revenue per Share compare to A and NTRA?
IDEXX Laboratories' Cyclically Adjusted Revenue per Share of €35.84 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current Cyclically Adjusted Revenue per Share is €35.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €551.89, compared to a current price of €486.20 — trading 11.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €35.84. IDEXX Laboratories' overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Cyclically Adjusted Revenue per Share is €35.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of €486.20 is trading 11.9% below its estimated GF Value™ of €551.89. GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:IX1:

  • Cyclically Adjusted Revenue per Share: €35.84
  • GF Value™: €551.89 vs. price of €486.20 (11.9% below fair value)
  • GF Score™: 98/100

No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
98GF Score

Get the complete analysis for FRA:IX1

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€486.20
Price
€551.89
GF Value